ArticleNature communications2018
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Agnostic material classification using differential de Bruijn graphs of DNA imprints.bioRxiv : the preprint server for biology · 2026Article
- Review
- From randomness to recognition: modeling the evolution of DNA sequence information during enrichment for binding.Bioinformatics advances · 2026Article
- Article
- Differential RNA aptamer affinity profiling on plasma as a potential diagnostic tool for bladder cancer.NAR cancer · 2022Article
- Generative and interpretable machine learning for aptamer design and analysis of in vitro sequence selection.PLoS computational biology · 2022Article
- Recent advances in aptamer applications for analytical biochemistry.Analytical biochemistry · 2022Article
- Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.Breast cancer research : BCR · 2021Article
- The immune landscape of common CNS malignancies: implications for immunotherapy.Nature reviews. Clinical oncology · 2021Review
- FluCell-SELEX Aptamers as Specific Binding Molecules for Diagnostics of the Health Relevant Gut BacteriumInternational journal of molecular sciences · 2021Article
- The Diversity of a Polyclonal FluCell-SELEX Library Outperforms Individual Aptamers as Emerging Diagnostic Tools for the Identification of Carbapenem Resistant Pseudomonas aeruginosa.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes.Nucleic acids research · 2020Article
- The current state of molecular testing in the treatment of patients with solid tumors, 2019.CA: a cancer journal for clinicians · 2019Review
- Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?Molecular diagnosis & therapy · 2019Review
- Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model.Scientific reports · 2019Article
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.International journal of molecular sciences · 2019Review
- Recent Progress in European Advanced Therapy Medicinal Products and Beyond.Frontiers in bioengineering and biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Assessing the phenotypic diversity underlying tumour progression requires the identification of variations in the respective molecular interaction networks. Here we report proof-of-concept for a platform called poly-ligand profiling (PLP) that surveys these system states and distinguishes breast cancer patients who did or did not derive benefit from trastuzumab. We perform tissue-SELEX on breast cancer specimens to enrich single-stranded DNA (ssDNA) libraries that preferentially interact with molecular components associated with the two clinical phenotypes. Testing of independent sample sets verifies the ability of PLP to classify trastuzumab-treated patients according to their clinical outcomes with ROC-AUC of 0.78. Standard HER2 testing of the same patients gives a ROC-AUC of 0.47. Kaplan-Meier analysis reveals a median increase in benefit from trastuzumab-containing treatments of 300 days for PLP-positive compared to PLP-negative patients. If prospectively validated, PLP may increase success rates in precision oncology and clinical trials, thus improving both patient care and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.